SCHEMBL5886797

SCHEMBL5886797

COCCNc1nc(C)c2ccc(=O)n(-c3ccc(C(=O)NC4CC4)cc3)c2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 3/20 0.47
TTK P33981 3/20 0.41
RIPK2 O43353 1/20 0.40
RXFP1 Q9HBX9 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
HSD17B10 Q99714 1/20 0.39
ATM Q13315 1/20 0.39
THRB P10828 1/20 0.39
CYP2C9 P11712 1/20 0.38
MAPK14 Q16539 1/20 0.38
SMYD3 Q9H7B4 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 2/20 0.38
RAB9A P51151 2/20 0.38
PDE4B Q07343 1/20 0.36
NPC1 O15118 1/20 0.36
TSHR P16473 1/20 0.36
MAPK9 P45984 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5886987 0.91 MAPK8 (0.41) MAPK8TTKSMN1; SMN2MAPK14SMYD3
SCHEMBL5887442 0.90 SMYD3 (0.45) MAPK8TTKSMN1; SMN2SMYD3LMNA
SCHEMBL5886914 0.88 RAB9A (0.43) MAPK8TTKSMN1; SMN2THRBSMYD3
SCHEMBL5886859 0.86 MAPK14 (0.43) MAPK8TTKSMN1; SMN2MAPK14SMYD3
SCHEMBL5886879 0.86 LMNA (0.48) MAPK8TTKSMN1; SMN2ALDH1A1GAA
SCHEMBL5887490 0.86 MAPK8 (0.40) MAPK8TTKSMN1; SMN2THRBSMYD3
SCHEMBL5886835 0.86 MMP13 (0.43) MAPK8SMN1; SMN2ALDH1A1THRBMAPK14
SCHEMBL5887030 0.86 MAPK14 (0.43) MAPK8TTKSMN1; SMN2GAAMAPK14
SCHEMBL5887074 0.85 MAPK14 (0.49) TTKSMN1; SMN2MAPK14RAB9ANPC1
SCHEMBL5887014 0.84 CDK5 (0.39) MAPK8SMN1; SMN2ALDH1A1HSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US claimed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US claimed
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors TERT, TERF2, TERF2IP MAPK8 770/4885TTK 681/4885RIPK2 2401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.